233 related articles for article (PubMed ID: 28235141)
1. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
[TBL] [Abstract][Full Text] [Related]
2. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
[TBL] [Abstract][Full Text] [Related]
3. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
[TBL] [Abstract][Full Text] [Related]
4. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Park HS; Lim SM; Kim S; Kim S; Kim HR; Kwack K; Lee MG; Kim JH; Moon YW
PLoS One; 2016; 11(4):e0154133. PubMed ID: 27105424
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
[TBL] [Abstract][Full Text] [Related]
6. Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.
Vashistha V; Katsoulakis E; Guo A; Price M; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Feb; 7():e2200518. PubMed ID: 36787508
[TBL] [Abstract][Full Text] [Related]
7. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
8. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
9. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
10. Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing.
Roman Souza G; Abdalla A; Arora S; Mahadevan D
Invest New Drugs; 2022 Jun; 40(3):643-649. PubMed ID: 35038126
[TBL] [Abstract][Full Text] [Related]
11. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
[TBL] [Abstract][Full Text] [Related]
12. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
14. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
17. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
18. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine.
Lee H; Cho YA; Kim DG; Cho EY
Cancer Res Treat; 2024 Jan; 56(1):149-161. PubMed ID: 37591784
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]